A groundbreaking new drug has been approved by the FDA to slow the progression of Alzheimer’s disease in its early stages, offering new hope for millions of Americans affected by the condition.
The drug, Kisunla, becomes the third treatment approved by the FDA that targets the underlying causes of Alzheimer’s disease. It’s designed to slow cognitive decline, giving individuals more time to maintain their independence.
Dr. David Ferguson, a financial health care advocate from De Pere, highlights the importance of this approval in combating Alzheimer’s.
“This new approval is a big step forward in the fight against the disease,” said Ferguson. “The drug helps remove a protein long thought to be associated with cognitive decline. It represents a new class of drug researched to target one of the underlying mechanisms of dementia.”
According to the Alzheimer’s Association, almost 7 million Americans are currently living with Alzheimer’s disease, including over 110,000 in Wisconsin.
Nina Sparano